In Vitro and In Vivo Evaluation of Ferric-Hyaluronate Implants for Delivery of Amikacin Sulfate to the Tarsocrural Joint of Horses
To assess the antimicrobial elution characteristics, toxicity, and antimicrobial activity of amikacin-impregnated ferric-hyaluronate implants (AI-FeHAI) for amikacin delivery to the tarsocrural joint of horses. Experimental study. AI-FeHAI implants, equine cartilage, and synovium, and horses (n=6)....
Gespeichert in:
| Veröffentlicht in: | Veterinary surgery 2009-06, Vol.38 (4), p.498-505 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 505 |
|---|---|
| container_issue | 4 |
| container_start_page | 498 |
| container_title | Veterinary surgery |
| container_volume | 38 |
| creator | CRIBB, NICOLA C BOURÉ, LUDOVIC P BRAD HANNA, W.J AKENS, MARGARETE K MATTSON, SHAWN E MONTEITH, GABRIELLE J WEESE, J. SCOTT |
| description | To assess the antimicrobial elution characteristics, toxicity, and antimicrobial activity of amikacin-impregnated ferric-hyaluronate implants (AI-FeHAI) for amikacin delivery to the tarsocrural joint of horses. Experimental study. AI-FeHAI implants, equine cartilage, and synovium, and horses (n=6). In vitro study: Five AI-FeHAI were placed in saline solution with daily replacement until implant degradation. Eluent was tested for amikacin concentration and bioactivity. Synovial and cartilage explants were incubated in the presence or absence of AI-FeHAI for 72 hours and subsequently assessed for morphology, viability, and composition. Synovial explants were incubated with Staphylococcus aureus in the presence or absence of AI-FeHAI. Spent medium was cultured daily and explants were assessed for morphology and viability after 96 hours. In vivo study: AI-FeHAI were placed in 6 tarsocrural joints. Standard cytologic analysis and amikacin concentration (SFAC) were determined in synovia obtained regularly for 28 days thereafter. Similar analyses were conducted after a single intra-articular injection of amikacin 6 months later. In vitro study: Amikacin concentrations exceeded 16 μg/mL and inhibited S. aureus growth for 8 days. AI-FeHAI had no effect on cartilage explants. AI-FeHAI eliminated bacteria from synovial explants. In vitro study: After AI-FeHAI placement, SFAC was highest (140.78+63.81 μg/mL) at first sampling time. By 24 hours SFAC was |
| doi_str_mv | 10.1111/j.1532-950X.2009.00518.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20746495</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20746495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4888-c4e8533dcb31681a04cc60a208c51fccd4cf21f163093279c90a54cbea2d968d3</originalsourceid><addsrcrecordid>eNqNkk1v0zAAhi0EYqXwF8DiwC3Bn4lzQZrKthZVgNR2cLNcxwF3adzZSWmv--VzmmpInPDBn49f2X4MAMQoxbF83KSYU5IUHP1MCUJFihDHIj08A6OnhedghHCGE8qK4gK8CmGDIskYfQkucMGpyHIyAg-zBt7a1juomhKeBnsHr_aq7lRrXQNdBa-N91Yn02Oc9K5RrYGz7a5WTRtg5Tz8bGq7N_7Ys5dbe6e0beCiq6uebB1sfxu4VD447TuvavjF2abt4anzwYTX4EWl6mDenNsxWF1fLSfTZP7tZja5nCeaCSFibQSntNRrijOBFWJaZ0gRJDTHldYl0xXBFc4oKijJC10gxZleG0XKIhMlHYMPQ-7Ou_vOhFZubdCmjhcxrguSoJxlLL7MGLz_B9y4zjfxbJJgnmGCOIqQGCDtXQjeVHLn7Vb5o8RI9pLkRvYuZO9C9pLkSZI8xK1vz_ndemvKvxvPViLwaQD-2Noc_ztY3i5Wp24MSIYAG1pzeApQ_k5mOc25_PH1Ri7n-Zx9n2A5ify7ga-Uk-qXt0GuFgRhGn8QFZRy-ghfArlI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>215612050</pqid></control><display><type>article</type><title>In Vitro and In Vivo Evaluation of Ferric-Hyaluronate Implants for Delivery of Amikacin Sulfate to the Tarsocrural Joint of Horses</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>CRIBB, NICOLA C ; BOURÉ, LUDOVIC P ; BRAD HANNA, W.J ; AKENS, MARGARETE K ; MATTSON, SHAWN E ; MONTEITH, GABRIELLE J ; WEESE, J. SCOTT</creator><creatorcontrib>CRIBB, NICOLA C ; BOURÉ, LUDOVIC P ; BRAD HANNA, W.J ; AKENS, MARGARETE K ; MATTSON, SHAWN E ; MONTEITH, GABRIELLE J ; WEESE, J. SCOTT</creatorcontrib><description>To assess the antimicrobial elution characteristics, toxicity, and antimicrobial activity of amikacin-impregnated ferric-hyaluronate implants (AI-FeHAI) for amikacin delivery to the tarsocrural joint of horses. Experimental study. AI-FeHAI implants, equine cartilage, and synovium, and horses (n=6). In vitro study: Five AI-FeHAI were placed in saline solution with daily replacement until implant degradation. Eluent was tested for amikacin concentration and bioactivity. Synovial and cartilage explants were incubated in the presence or absence of AI-FeHAI for 72 hours and subsequently assessed for morphology, viability, and composition. Synovial explants were incubated with Staphylococcus aureus in the presence or absence of AI-FeHAI. Spent medium was cultured daily and explants were assessed for morphology and viability after 96 hours. In vivo study: AI-FeHAI were placed in 6 tarsocrural joints. Standard cytologic analysis and amikacin concentration (SFAC) were determined in synovia obtained regularly for 28 days thereafter. Similar analyses were conducted after a single intra-articular injection of amikacin 6 months later. In vitro study: Amikacin concentrations exceeded 16 μg/mL and inhibited S. aureus growth for 8 days. AI-FeHAI had no effect on cartilage explants. AI-FeHAI eliminated bacteria from synovial explants. In vitro study: After AI-FeHAI placement, SFAC was highest (140.78+63.81 μg/mL) at first sampling time. By 24 hours SFAC was <16 μg/mL. After intra-articular injection, SFAC was the highest (377.91 ± 40.15 μg/mL) at first sampling time. By 48 hours SFAC was <16 μg/mL. A single intra-articular amikacin injection demonstrated superior pharmacokinetics than AI-FeHAI prepared as described. AI-FeHAI cannot be recommended for clinical use.</description><identifier>ISSN: 0161-3499</identifier><identifier>EISSN: 1532-950X</identifier><identifier>DOI: 10.1111/j.1532-950X.2009.00518.x</identifier><identifier>PMID: 19538672</identifier><language>eng</language><publisher>Malden, USA: Malden, USA : Blackwell Publishing Inc</publisher><subject>Absorbable Implants - veterinary ; Amikacin - administration & dosage ; Amikacin - pharmacokinetics ; amikacin sulfate ; Animals ; Antibiotics ; antimicrobial agents ; blood composition ; cartilage ; cell biology ; Clinical outcomes ; Drug Delivery Systems ; drug implants ; ferric-hyaluronate implants ; horse diseases ; Horses ; hyaluronic acid ; Hyaluronic Acid - chemistry ; in vitro studies ; in vivo studies ; Injections, Intra-Articular - veterinary ; Iron - chemistry ; joint diseases ; Joints ; joints (animal) ; pharmacokinetics ; Staphylococcus aureus ; synovial fluid ; tarsocrural joint ; Tarsus, Animal ; toxicity ; Transplants & implants ; veterinary drugs ; Veterinary medicine ; viability</subject><ispartof>Veterinary surgery, 2009-06, Vol.38 (4), p.498-505</ispartof><rights>Copyright 2009 by The American College of Veterinary Surgeons</rights><rights>2009 American College of Veterinary Surgeons</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4888-c4e8533dcb31681a04cc60a208c51fccd4cf21f163093279c90a54cbea2d968d3</citedby><cites>FETCH-LOGICAL-c4888-c4e8533dcb31681a04cc60a208c51fccd4cf21f163093279c90a54cbea2d968d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1532-950X.2009.00518.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1532-950X.2009.00518.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19538672$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CRIBB, NICOLA C</creatorcontrib><creatorcontrib>BOURÉ, LUDOVIC P</creatorcontrib><creatorcontrib>BRAD HANNA, W.J</creatorcontrib><creatorcontrib>AKENS, MARGARETE K</creatorcontrib><creatorcontrib>MATTSON, SHAWN E</creatorcontrib><creatorcontrib>MONTEITH, GABRIELLE J</creatorcontrib><creatorcontrib>WEESE, J. SCOTT</creatorcontrib><title>In Vitro and In Vivo Evaluation of Ferric-Hyaluronate Implants for Delivery of Amikacin Sulfate to the Tarsocrural Joint of Horses</title><title>Veterinary surgery</title><addtitle>Vet Surg</addtitle><description>To assess the antimicrobial elution characteristics, toxicity, and antimicrobial activity of amikacin-impregnated ferric-hyaluronate implants (AI-FeHAI) for amikacin delivery to the tarsocrural joint of horses. Experimental study. AI-FeHAI implants, equine cartilage, and synovium, and horses (n=6). In vitro study: Five AI-FeHAI were placed in saline solution with daily replacement until implant degradation. Eluent was tested for amikacin concentration and bioactivity. Synovial and cartilage explants were incubated in the presence or absence of AI-FeHAI for 72 hours and subsequently assessed for morphology, viability, and composition. Synovial explants were incubated with Staphylococcus aureus in the presence or absence of AI-FeHAI. Spent medium was cultured daily and explants were assessed for morphology and viability after 96 hours. In vivo study: AI-FeHAI were placed in 6 tarsocrural joints. Standard cytologic analysis and amikacin concentration (SFAC) were determined in synovia obtained regularly for 28 days thereafter. Similar analyses were conducted after a single intra-articular injection of amikacin 6 months later. In vitro study: Amikacin concentrations exceeded 16 μg/mL and inhibited S. aureus growth for 8 days. AI-FeHAI had no effect on cartilage explants. AI-FeHAI eliminated bacteria from synovial explants. In vitro study: After AI-FeHAI placement, SFAC was highest (140.78+63.81 μg/mL) at first sampling time. By 24 hours SFAC was <16 μg/mL. After intra-articular injection, SFAC was the highest (377.91 ± 40.15 μg/mL) at first sampling time. By 48 hours SFAC was <16 μg/mL. A single intra-articular amikacin injection demonstrated superior pharmacokinetics than AI-FeHAI prepared as described. AI-FeHAI cannot be recommended for clinical use.</description><subject>Absorbable Implants - veterinary</subject><subject>Amikacin - administration & dosage</subject><subject>Amikacin - pharmacokinetics</subject><subject>amikacin sulfate</subject><subject>Animals</subject><subject>Antibiotics</subject><subject>antimicrobial agents</subject><subject>blood composition</subject><subject>cartilage</subject><subject>cell biology</subject><subject>Clinical outcomes</subject><subject>Drug Delivery Systems</subject><subject>drug implants</subject><subject>ferric-hyaluronate implants</subject><subject>horse diseases</subject><subject>Horses</subject><subject>hyaluronic acid</subject><subject>Hyaluronic Acid - chemistry</subject><subject>in vitro studies</subject><subject>in vivo studies</subject><subject>Injections, Intra-Articular - veterinary</subject><subject>Iron - chemistry</subject><subject>joint diseases</subject><subject>Joints</subject><subject>joints (animal)</subject><subject>pharmacokinetics</subject><subject>Staphylococcus aureus</subject><subject>synovial fluid</subject><subject>tarsocrural joint</subject><subject>Tarsus, Animal</subject><subject>toxicity</subject><subject>Transplants & implants</subject><subject>veterinary drugs</subject><subject>Veterinary medicine</subject><subject>viability</subject><issn>0161-3499</issn><issn>1532-950X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk1v0zAAhi0EYqXwF8DiwC3Bn4lzQZrKthZVgNR2cLNcxwF3adzZSWmv--VzmmpInPDBn49f2X4MAMQoxbF83KSYU5IUHP1MCUJFihDHIj08A6OnhedghHCGE8qK4gK8CmGDIskYfQkucMGpyHIyAg-zBt7a1juomhKeBnsHr_aq7lRrXQNdBa-N91Yn02Oc9K5RrYGz7a5WTRtg5Tz8bGq7N_7Ys5dbe6e0beCiq6uebB1sfxu4VD447TuvavjF2abt4anzwYTX4EWl6mDenNsxWF1fLSfTZP7tZja5nCeaCSFibQSntNRrijOBFWJaZ0gRJDTHldYl0xXBFc4oKijJC10gxZleG0XKIhMlHYMPQ-7Ou_vOhFZubdCmjhcxrguSoJxlLL7MGLz_B9y4zjfxbJJgnmGCOIqQGCDtXQjeVHLn7Vb5o8RI9pLkRvYuZO9C9pLkSZI8xK1vz_ndemvKvxvPViLwaQD-2Noc_ztY3i5Wp24MSIYAG1pzeApQ_k5mOc25_PH1Ri7n-Zx9n2A5ify7ga-Uk-qXt0GuFgRhGn8QFZRy-ghfArlI</recordid><startdate>200906</startdate><enddate>200906</enddate><creator>CRIBB, NICOLA C</creator><creator>BOURÉ, LUDOVIC P</creator><creator>BRAD HANNA, W.J</creator><creator>AKENS, MARGARETE K</creator><creator>MATTSON, SHAWN E</creator><creator>MONTEITH, GABRIELLE J</creator><creator>WEESE, J. SCOTT</creator><general>Malden, USA : Blackwell Publishing Inc</general><general>Blackwell Publishing Inc</general><general>Blackwell Publishing Ltd</general><scope>FBQ</scope><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>M7Z</scope><scope>P64</scope><scope>7QL</scope><scope>7QO</scope><scope>C1K</scope></search><sort><creationdate>200906</creationdate><title>In Vitro and In Vivo Evaluation of Ferric-Hyaluronate Implants for Delivery of Amikacin Sulfate to the Tarsocrural Joint of Horses</title><author>CRIBB, NICOLA C ; BOURÉ, LUDOVIC P ; BRAD HANNA, W.J ; AKENS, MARGARETE K ; MATTSON, SHAWN E ; MONTEITH, GABRIELLE J ; WEESE, J. SCOTT</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4888-c4e8533dcb31681a04cc60a208c51fccd4cf21f163093279c90a54cbea2d968d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Absorbable Implants - veterinary</topic><topic>Amikacin - administration & dosage</topic><topic>Amikacin - pharmacokinetics</topic><topic>amikacin sulfate</topic><topic>Animals</topic><topic>Antibiotics</topic><topic>antimicrobial agents</topic><topic>blood composition</topic><topic>cartilage</topic><topic>cell biology</topic><topic>Clinical outcomes</topic><topic>Drug Delivery Systems</topic><topic>drug implants</topic><topic>ferric-hyaluronate implants</topic><topic>horse diseases</topic><topic>Horses</topic><topic>hyaluronic acid</topic><topic>Hyaluronic Acid - chemistry</topic><topic>in vitro studies</topic><topic>in vivo studies</topic><topic>Injections, Intra-Articular - veterinary</topic><topic>Iron - chemistry</topic><topic>joint diseases</topic><topic>Joints</topic><topic>joints (animal)</topic><topic>pharmacokinetics</topic><topic>Staphylococcus aureus</topic><topic>synovial fluid</topic><topic>tarsocrural joint</topic><topic>Tarsus, Animal</topic><topic>toxicity</topic><topic>Transplants & implants</topic><topic>veterinary drugs</topic><topic>Veterinary medicine</topic><topic>viability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CRIBB, NICOLA C</creatorcontrib><creatorcontrib>BOURÉ, LUDOVIC P</creatorcontrib><creatorcontrib>BRAD HANNA, W.J</creatorcontrib><creatorcontrib>AKENS, MARGARETE K</creatorcontrib><creatorcontrib>MATTSON, SHAWN E</creatorcontrib><creatorcontrib>MONTEITH, GABRIELLE J</creatorcontrib><creatorcontrib>WEESE, J. SCOTT</creatorcontrib><collection>AGRIS</collection><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Veterinary surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CRIBB, NICOLA C</au><au>BOURÉ, LUDOVIC P</au><au>BRAD HANNA, W.J</au><au>AKENS, MARGARETE K</au><au>MATTSON, SHAWN E</au><au>MONTEITH, GABRIELLE J</au><au>WEESE, J. SCOTT</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro and In Vivo Evaluation of Ferric-Hyaluronate Implants for Delivery of Amikacin Sulfate to the Tarsocrural Joint of Horses</atitle><jtitle>Veterinary surgery</jtitle><addtitle>Vet Surg</addtitle><date>2009-06</date><risdate>2009</risdate><volume>38</volume><issue>4</issue><spage>498</spage><epage>505</epage><pages>498-505</pages><issn>0161-3499</issn><eissn>1532-950X</eissn><abstract>To assess the antimicrobial elution characteristics, toxicity, and antimicrobial activity of amikacin-impregnated ferric-hyaluronate implants (AI-FeHAI) for amikacin delivery to the tarsocrural joint of horses. Experimental study. AI-FeHAI implants, equine cartilage, and synovium, and horses (n=6). In vitro study: Five AI-FeHAI were placed in saline solution with daily replacement until implant degradation. Eluent was tested for amikacin concentration and bioactivity. Synovial and cartilage explants were incubated in the presence or absence of AI-FeHAI for 72 hours and subsequently assessed for morphology, viability, and composition. Synovial explants were incubated with Staphylococcus aureus in the presence or absence of AI-FeHAI. Spent medium was cultured daily and explants were assessed for morphology and viability after 96 hours. In vivo study: AI-FeHAI were placed in 6 tarsocrural joints. Standard cytologic analysis and amikacin concentration (SFAC) were determined in synovia obtained regularly for 28 days thereafter. Similar analyses were conducted after a single intra-articular injection of amikacin 6 months later. In vitro study: Amikacin concentrations exceeded 16 μg/mL and inhibited S. aureus growth for 8 days. AI-FeHAI had no effect on cartilage explants. AI-FeHAI eliminated bacteria from synovial explants. In vitro study: After AI-FeHAI placement, SFAC was highest (140.78+63.81 μg/mL) at first sampling time. By 24 hours SFAC was <16 μg/mL. After intra-articular injection, SFAC was the highest (377.91 ± 40.15 μg/mL) at first sampling time. By 48 hours SFAC was <16 μg/mL. A single intra-articular amikacin injection demonstrated superior pharmacokinetics than AI-FeHAI prepared as described. AI-FeHAI cannot be recommended for clinical use.</abstract><cop>Malden, USA</cop><pub>Malden, USA : Blackwell Publishing Inc</pub><pmid>19538672</pmid><doi>10.1111/j.1532-950X.2009.00518.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-3499 |
| ispartof | Veterinary surgery, 2009-06, Vol.38 (4), p.498-505 |
| issn | 0161-3499 1532-950X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20746495 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Absorbable Implants - veterinary Amikacin - administration & dosage Amikacin - pharmacokinetics amikacin sulfate Animals Antibiotics antimicrobial agents blood composition cartilage cell biology Clinical outcomes Drug Delivery Systems drug implants ferric-hyaluronate implants horse diseases Horses hyaluronic acid Hyaluronic Acid - chemistry in vitro studies in vivo studies Injections, Intra-Articular - veterinary Iron - chemistry joint diseases Joints joints (animal) pharmacokinetics Staphylococcus aureus synovial fluid tarsocrural joint Tarsus, Animal toxicity Transplants & implants veterinary drugs Veterinary medicine viability |
| title | In Vitro and In Vivo Evaluation of Ferric-Hyaluronate Implants for Delivery of Amikacin Sulfate to the Tarsocrural Joint of Horses |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T14%3A10%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vitro%20and%20In%20Vivo%20Evaluation%20of%20Ferric-Hyaluronate%20Implants%20for%20Delivery%20of%20Amikacin%20Sulfate%20to%20the%20Tarsocrural%20Joint%20of%20Horses&rft.jtitle=Veterinary%20surgery&rft.au=CRIBB,%20NICOLA%20C&rft.date=2009-06&rft.volume=38&rft.issue=4&rft.spage=498&rft.epage=505&rft.pages=498-505&rft.issn=0161-3499&rft.eissn=1532-950X&rft_id=info:doi/10.1111/j.1532-950X.2009.00518.x&rft_dat=%3Cproquest_cross%3E20746495%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=215612050&rft_id=info:pmid/19538672&rfr_iscdi=true |